薬物動態
Print ISSN : 0916-1139
塩酸イリノテカンとその活性代謝物の胆汁排泄機構と副作用との関連:cMOATおよびP糖蛋白(MDR)の関与
加藤 将夫儲 暁岩堀川 雅人鈴木 洋史杉山 雄一
著者情報
ジャーナル フリー

1998 年 13 巻 supplement 号 p. 102-103

詳細
抄録
A frequent limiting side-effect of irinotecan, CPT-11, is its gastrointestinal toxicity (diarrhea) thought to be related to the biliary excretion of CPT-11 and its metabolites. Accordingly, we have investigated their biliary excretion mechanism. Our in vivo pharmacokinetic studies in rats revealed that the biliary excretion clearance of the four anionic forms of CPT-11 and its metabolites ways much lower in Eisai hyperbilirubinemic rats (EHBR) with a genetic deficiency of the hepatic canalicular multispecific organic anion transporter (cMOAT). Detailed analysis using isolated liver bile canalicular membrane vesicles led to identify the multiplicity of transport systems. Such multiple primary active transport systems are also responsible for the biliary excretion of CPT-11 and its metabolites in humans, and the major transport systemforOPT-11 differs fromthat forthe othertwo compounds. Greater degree of inter-CMV variability in the uptake of SN-38 and SN38-Glu may imply that interindividual variability in their biliary excretion might contribute to the interpatient variability in the toxicity caused by CPT-11.
著者関連情報
© 日本薬物動態学会
前の記事 次の記事
feedback
Top